BTS
TGTX icon

BB&T Securities’s TG Therapeutics TGTX Stock Holding History

BB&T Securities’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-16,650
Closed -$218K – 1643
2018
Q2 		$218K Sell
16,650
-5,700
-26% -$78.4K ﹤0.01% 1418
2018
Q1 		$317K Sell
22,350
-11,350
-34% -$145K ﹤0.01% 1216
2017
Q4 		$276K Buy
33,700
+20,400
+153% +$178K ﹤0.01% 1217
2017
Q3 		$157K Sell
13,300
-3,649
-22% -$41.6K ﹤0.01% 1324
2017
Q2 		$170K Buy
16,949
+6,549
+63% +$73.3K ﹤0.01% 1312
2017
Q1 		$121K Buy
+10,400
New +$74.7K ﹤0.01% 1206

Other funds holding TGTX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $49.3B AUM 36.45% 1-Year Est. Return

BB&T Securities's TGTX Position: Q3 2018 in Review

BB&T Securities sold out of TG Therapeutics (TGTX) in Q3 2018, closing a stake of 16,650 shares — an estimated $218K sold.

BB&T Securities first reported a position in TGTX in Q1 2017 and held it in 6 quarters. The position peaked at $317K in Q1 2018. 128 funds tracked by Wall St. Rank hold TGTX as of Q3 2018.

  • BB&T Securities reported no remaining TG Therapeutics position as of Q3 2018 after selling out during the quarter.
  • BB&T Securities sold 16,650 TG Therapeutics shares in Q3 2018, an estimated $218K.
  • BB&T Securities first reported a position in TG Therapeutics in Q1 2017 and held it in 6 quarters.
  • BB&T Securities's TG Therapeutics position peaked at $317K in Q1 2018.
  • 128 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2018.

Based on BB&T Securities's 13F filing for Q3 2018, filed 14 Nov 2018.